AzTrials
AzTrials

HIV PreventionSMaaRTNCT06566417

Social Media as a Risk Tool for HIV Prevention Needs

An observational study of HIV Prevention and HIV Preexposure Prophylaxis, run by Massachusetts General Hospital at 1 site in Kenya.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The impact of effective HIV prevention tools is limited because many people do not know that they are at risk for HIV acquisition, despite the availability of various risk assessment scores and criteria. Read more about this study

Who is it for?
Ages 18 to 24 years, women onlyHealthy volunteers can take part
Conditions the study is for
HIV Prevention, HIV Preexposure Prophylaxis
How many people
400 participants
Where
1 siteKenya
Study dates
1 Feb 2024to 20 Jul 2025
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 24 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Study population: Research assistants will recruit young Kenyan women (ages 18-24), attending one of four clinics for any health services. Smart phone ownership and use of SMS, WhatsApp, or other social media is required.

Who may be able to join

  • Identifying as a young woman (age 18-24 years)
  • Attending clinic for any health services, including PrEP and HIV testing
  • Smart phone ownership
  • Ability to understand Kiswahili, DhoLuo, and/or English
  • Use of SMS, WhatsApp, and/or other types of social media

Who cannot join

  • Inability to provide informed consent (e.g., intoxication, developmental delay)

Trial locations and contacts

1 site in 1 country.

Kenya1 site
  • KEMRI

    Kisumu

Other trials in Kenya

About this study

Official title: Use of Sentiment Analysis and Social Media to Understand HIV Prevention Needs Among Young Women in Kenya

The impact of effective HIV prevention tools is limited because many people do not know that they are at risk for HIV acquisition, despite the availability of various risk assessment scores and criteria. This proposal aims to use a novel data science approach to assessing HIV prevention needs among 400 young women in Kisumu, Kenya- namely, topic modeling and network analysis of text and/or social media messages (e.g., WhatsApp, Instagram, Twitter). The study will involve in-depth assessment of relevant ethical and logistical factors to ensure appropriate and optimized use of a sentiment analysis tool for implementation in routine clinical care.

Read the detailed description

In the Social Media as a Risk Tool (SMaaRT) Study, the investigators hypothesize that topic modeling of SMS/social media data combined with network analysis among young women in Kenya will correlate well with existing HIV risk scales and ultimately yield a better understanding of HIV prevention needs. The investigators propose the following aims:

  1. Explore ethical factors that may influence analysis of SMS and social media messages. Research assistants will conduct individual qualitative interviews with up to 32 young women (16 who would and 16 who would not provide SMS/social media data, stratified among four clinic sites) and one focus group of five Kenyan bioethicists. Questions will explore ethical concerns from individual and bystander (e.g., contacts involved in SMS/social media) perspectives and differences in ethical issues by type of social media (e.g., conversations vs posts). Follow-up interviews will be conducted with the women who provide SMS and/or social media data (in Aim 2).
  2. Conduct topic modeling and network analysis of SMS and social media messages to predict HIV prevention needs among young women in Kenya. Working with four clinical sites in Kisumu, study staff will ask approximately 400 women (ages 18-24) seeking HIV testing, PrEP, and other health services to download six months of SMS/social media messages (e.g., WhatsApp, Instagram, Twitter) as a one-time procedure. For those providing data, research assistants will assess social networks engaged via SMS/social media (e.g., anonymously labeled as peers, sexual partners), administer multiple HIV risk assessments (e.g., VOICE, Wand risk scores), and obtain HIV test results. Data analysts will use automated structural topic modelling to determine "topics" (word clusters) and assess for association with other risk assessments (primary outcome) and HIV test results (exploratory outcome), and will also evaluate the impact of social networks, SMS/social media type, data volume, and language type on outcomes. Data collection and analysis will conform to Aim 1 findings.
  3. Assess practical factors that may influence use of a sentiment analysis tool in routine care. In a needs assessment based on Implementation Mapping, research assistants will conduct four focus groups with five staff per clinic and two focus groups with five young women each to explore staffing best suited to implement a sentiment analysis tool and how it could be best integrated into routine care. The investigators will also assess available resources to determine optimal efficiency in developing a preliminary implementation strategy.
Keywords
HIV prevention, HIV Pre-exposure prophylaxis, Sentiment analysis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Association of Artificial Intelligence Measure Datasets With the Wand Risk Score

    The investigators will compare the above-noted measure datasets with the Wand risk score as assessed in the study participants at the time of SMS/social media data collection.

    The Wand risk score is an empirically validated HIV prediction tool designed to estimate the probability of HIV acquisition in women. It calculates a total score (max 50 pts): age <20 years (11 pts), 20-24 years (10 pts), 25-29 years (6 pts), 30+ years (0 pts); marital status of single/not cohabitating (13 pts), married/cohabitating (0 pts); # sexual partners in last 3 months of 3 or more (5 pts), <3 (0 pts); age at sexual debut of <16 years (3 pts), 16+ years (0 pts); parity (# of births) of 0-1 births (10 pts), 2 births (8 pts), 3+ births (0 pts); ever diagnosed with an STI as yes (4 pts), no (0 pts); and use of injectable contraception as yes (4 pts), no (0 pts). A higher score denotes a higher HIV risk. The total possible range is 0-50.

    Measured: 6 months of data given at one time

  2. Association of Artificial Intelligence Measure Datasets With the VOICE Risk Score

    Analysts will examine 6 months of SMS/social media message content from each of the 400 study participants using three computational linguistic methods: 1) sentiment, valence, and arousal analysis; 2) topic modeling; 3) simple textual counts. Analysts will also perform network analysis with up to 20 contacts from each participant to understand how often and with which parties the participant communicates most frequently. These networks will be examined temporally to see if any of the connections have grown or weakened over time.

    The VOICE risk score (modified to not use biological markers) is a measure of behavioral and demographic factors to determine HIV risk: <25 y/o (2 pts), unmarried or not living with a partner (2 pts), primary partner has other partners (2 pts), partner does not provide financial support (1 pt), alcohol use in the last 3 months (1 pt). A higher score denotes a greater HIV risk. The total possible range is 0-8.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Aug 2024
  2. Study start1 Feb 2024
  3. Primary completion15 May 2025
  4. Study completion20 Jul 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
400 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06566417
Sponsor's protocol ID
2023P001625
Other IDs
1R21MH132436-01A1
Acronym
SMaaRT
Status last verified
Aug 2026
First submitted
30 Jul 2024
Last updated
31 Aug 2026
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: This project will release and share final de-identified research data and materials from NIH-supported research for use by other researchers in a timely manner. Due to the sensitive nature of the SMS/social media messages, that data will be deleted at the conclusion of the study.

Questions about this trial

What is this clinical trial studying?

An observational study of HIV Prevention and HIV Preexposure Prophylaxis, run by Massachusetts General Hospital at 1 site in Kenya.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Kenya. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 31 Aug 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Association of Artificial Intelligence Measure Datasets With the Wand Risk Score (time frame: 6 months of data given at one time). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in